Latest news with #ExtraordinaryGeneralMeeting
Yahoo
23-05-2025
- Business
- Yahoo
EVS Invites Its Shareholders to a Postponed Extraordinary General Meeting on June 10, 2025
EVS INVITES ITS SHAREHOLDERS TO A POSTPONED EXTRAORDINARY GENERAL MEETING ON JUNE 10, 2025 As already communicated on May 20, 2025, due to the lack of attendance quorum, the Extraordinary General Meeting of EVS Broadcast Equipment SA convened on May 20, 2025 is postponed to June 10, 2025, at 12:00 pm, at its registered office in Liège, to deliberate on the agenda available on the website of the company (see link below). The Board of Directors will propose to this effect to the Shareholders to approve the issuance of warrants. The convocation and all documents relating to the General Meeting of June 10, 2025 are available on the website of EVS Broadcast Equipment at About EVS We create return on emotion EVS is globally recognized as a leading provider in live video technology for broadcast and new media productions. Spanning the entire production process, EVS solutions are trusted by production teams worldwide to deliver the most gripping live sports images, buzzing entertainment shows and breaking news to billions of viewers every day – and in real time. As we continue to expand our footprint, our dedication to sustainable growth for both our business and the industry is clearly demonstrated through our ESG strategy. This commitment is not only reflected in our results, but also in our high ratings from different agencies. Headquartered in Liège, Belgium, the company has a global presence with offices in Australia, Asia, the Middle East, Europe, North and Latin America, employing over 700 team members and ensuring sales, training, and technical support to more than 100 countries. EVS is a public company traded on Euronext Brussels: EVS, ISIN: BE0003820371. EVS is, amongst others, part of the Euronext Tech Leaders and Euronext BEL Mid indices. Media Contacts For more info about this press release, or to set up an interview with EVS, please contact: Veerle De Wit – Chief Financial Officer Tel: +32 4 361 7004 – Email: Sébastien Verlaine – Senior Brand & Corporate Communications Manager Tel: +32 4 361 5809 – Email: Forward Looking Statements This press release contains forward-looking statements with respect to the business, financial condition, and results of operations of EVS and its affiliates. These statements are based on the current expectations or beliefs of EVS's management and are subject to a number of risks and uncertainties that could cause actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. These risks and uncertainties relate to changes in technology and market requirements, the company's concentration on one industry, decline in demand for the company's products and those of its affiliates, inability to timely develop and introduce new technologies, products and applications, and loss of market share and pressure on pricing resulting from competition which could cause the actual results or performance of the company to differ materially from those contemplated in such forward-looking statements. EVS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Attachment Press release in PDF formatError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
20-05-2025
- Business
- Business Upturn
Unifiedpost Group rebrands to Banqup Group, reinforcing its position as a pure-play SaaS provider
By GlobeNewswire Published on May 21, 2025, 01:00 IST Press Release – Regulated Information Unifiedpost Group rebrands to Banqup Group, reinforcing its position as a pure-play SaaS provider La Hulpe, Belgium – 20 May 2025, 22:00 CET – REGULATED INFORMATION – Banqup Group SA, formerly Unifiedpost Group SA, (Euronext: UPG) (Banqup, Company), a leading provider of integrated business communications solutions, held an Extraordinary General Meeting (EGM) and Annual General Meeting (AGM). The shareholders approved all proposed resolutions (here), including: EGM: Strategic rebranding from Unifiedpost Group SA to Banqup Group SA across the Group. This further underpins our focus on core digital services and aligns our business as a pure-play SaaS provider. The rebranding offers our stakeholders a clear understanding of our product and value proposition, reinforcing our commitment to growth in e-invoicing and payment solutions. AGM: Enhanced governance with the approval of the updated remuneration policy and the appointment of four new Board members: Nicolas de Beco, representing Beco Global Consulting LLC, as executive director Nathalie Van Den Haute, representing Quilaudem BV, as non-executive director Koen Hoffman, representing Ahok BV, as an independent director Leanne Kemp as an independent director The minutes, voting results and presentation of the AGM will be available on the shareholder page (here) in the coming days. Financial Calendar: 22 May 2025: Publication of the Q1 2025 business update 26 August 2025: Publication of the H1 2025 results (webcast) 13 November 2025: Publication of the Q3 2025 business update ContactAlex NicollInvestor RelationsBanqup Group [email protected] About Banqup Group Banqup Group delivers integrated cloud-based SaaS solutions to streamline business transactions across the entire lifecycle, from e-invoicing and e-payments to tax reporting. Banqup, our solution for businesses, unifies purchase-to-pay, order-to-cash, e-invoicing compliance, and e-payments into one secure platform, removing the complexity of juggling disconnected tools. eFaktura World, our solution for governments, is a comprehensive digital platform designed for tax administrations to implement e-invoicing and streamline both B2G and B2B tax reporting flows. To learn more about Banqup Group and our solutions, please visit our website: Unifiedpost Group | Global leaders in digital solutions Cautionary note regarding forward-looking statements: The statements contained herein may include prospects, statements of future expectations, opinions, and other forward-looking statements in relation to the expected future performance of Banqup Group and the markets in which it is active. Such forward-looking statements are based on management's current views and assumptions regarding future events. By nature, they involve known and unknown risks, uncertainties, and other factors that appear justified at the time at which they are made but may not turn out to be accurate. Actual results, performance or events may, therefore, differ materially from those expressed or implied in such forward-looking statements. Except as required by applicable law, Banqup Group does not undertake any obligation to update, clarify or correct any forward-looking statements contained in this press release in light of new information, future events or otherwise and disclaims any liability in respect hereto. The reader is cautioned not to place undue reliance on forward-looking statements. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
16-05-2025
- Business
- Yahoo
Information regarding the results of the vote on the resolutions presented (and all adopted) at the Annual General Meeting on May 15, 2025
Information regarding the results of the vote on the resolutions presented (and all adopted) at the Annual General Meeting on May 15, 2025 Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, held its Annual General Meeting on May 15, 2025, in Paris. A poll was held on each of the resolutions proposed. The results of the polls are set out below. Number of shareholders present, represented or voting by mail at the Ordinary General Meeting (OGM): 867 Number of shareholders present, represented or voting by mail at the Extraordinary General Meeting (EGM): 867 Number of voting rights exercisable as of May 15, 2025: 220,371,887 Total votes represented in the vote on the resolutions submitted to OGM: 202,370,496 Total votes represented in the vote on the resolutions submitted to EGM: 202,370,496 Results of the polls on the resolutions proposed under the jurisdiction of the Annual General Meeting: Ordinary resolutions Votes for Votes against Abstention Status Votes % Votes % Votes 1 Approval of the statutory financial statements for the year ended December 31, 2024 202,353,232 99.99% 4,984 0.01% 12,280 Agreed 2 Approval of the consolidated financial statements for the year ended December 31, 2024 202,352,506 99.99% 5,408 0.01% 12,582 Agreed 3 Allocation of net income for the year ended December 31, 2024 202,345,581 99.99% 11,409 0.01% 13,506 Agreed 4 Renewal of the term of office as director of Sarah Caulliez 191,539,101 95.46% 9,114,170 4.54% 1,717,225 Agreed 5 Appointment of a new director (Mr. Alexis Grolin) 191,963,604 95.67% 8,686,713 4.33% 1,720,179 Agreed 6 Appointment of a new director (Mr. Bertrand Cousin) 191,901,337 95.64% 8,749,796 4.36% 1,719,363 Agreed 7 Approval of the components of the compensation due or awarded to the President of the Board of Directors, Laurence Mulliez, for the 2024 financial year 185,896,774 92.19% 15,755,370 7.81% 718,352 Agreed 8 Approval of the compensation due or awarded to the Chief Executive Officer, Sébastien Clerc, for the 2024 financial year 188,753,931 94.39% 11,224,651 5.61% 2,391,914 Agreed 9 Vote on information relating to the 2024 compensation of the corporate officers (excluding executive corporate officers) set out in Article L22-10-9 of the French Commercial Code 186,355,873 93.99% 11,922,637 6.01% 4,091,986 Agreed 10 Approval of the 2025 compensation policy for corporate officers 200,220,113 99.91% 182,997 0.09% 1,967,386 Agreed 11 Approval of the 2025 compensation policy for the President of the Board of Directors 185,898,806 92.19% 15,748,751 7.81% 722,939 Agreed 12 Approval of the 2025 compensation policy for the Chief Executive Officer 191,759,291 95.68% 8,649,597 4.32% 1,961,608 Agreed 13 Determination of the overall compensation allocated to the members of the Board of Directors 200,218,372 99.91% 188,933 0.09% 1,963,191 Agreed 14 Authorization for the Board of Directors to purchase the Company's own shares 196,335,323 97.02% 6,028,019 2.98% 7,154 Agreed 15 Authorization to be granted to the Board of Directors to reduce the share capital by cancelling treasury shares 199,024,882 98.35% 3,337,323 1.65% 8,291 Agreed 16 Delegation of authority to the Board of Directors for the purpose of increasing the share capital without preferential subscription rights for a category of persons within the framework of implementing an equity or bond financing facility 183,223,915 90.54% 19,133,912 9.46% 12,669 Agreed 17 Delegation of authority to the Board of Directors for the purpose of increasing the share capital without preferential subscription rights for banks or financial institutions with the aim of promoting sustainable development in economic, social and/or environmental matters 183,221,130 90.54% 19,137,207 9.46% 12,159 Agreed 18 Delegation of authority to increase for the purpose of increasing the share capital, without preferential subscription for investors active in the field of energy, in particular renewable energies, and in the promotion of sustainable development in economic, social and/or environmental matters 183,222,922 90.54% 19,134,728 9.46% 12,846 Agreed 19 Delegation of authority to the Board of Directors to increase the share capital, with preferential subscription rights of the shareholders. 186,204,973 92.02% 16,158,574 7.98% 6,949 Agreed 20 Delegation of authority to the Board of Directors to increase share capital, with cancellation of shareholders' preferential subscription rights and public offering(s) (other than the offerings referred to in paragraph 1° of Article L. 411-2 of the French Monetary and Financial Code) 183,220,522 90.54% 19,138,867 9.46% 11,107 Agreed 21 Delegation of authority to the Board of Directors to increase share capital, with cancellation of shareholders' preferential subscription rights, in connection with offers referred to in paragraph 1° of Article L. 411-2 of the French Monetary and Financial Code. 182,792,794 90.52% 19,139,834 9.48% 437,868 Agreed 22 Delegation of authority to the Board of Directors to increase the number of securities to be issued in the event of a capital increase with or without preferential subscription rights 186,035,378 92.71% 14,627,440 7.29% 1,707,678 Agreed 23 Delegation of authority to issue ordinary shares and/or securities giving access to the Company's capital, in the event of a public offer with an exchange component initiated by the Company 183,599,179 90.73% 18,757,335 9.27% 13,982 Agreed 24 delegation of powers to increase the share capital to remunerate contributions in kind of equity securities or securities giving access to the capital of third-party companies outside a public exchange offer 185,946,332 91.89% 16,408,668 8.11% 15,496 Agreed 25 Setting the overall limits on the number of issues carried out by virtue of the above-mentioned delegations of authority 199,173,808 98.43% 3,181,897 1.57% 14,791 Agreed 26 Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital by issuing shares and securities convertible to capital of the Company without preferential subscription rights for shareholders for the benefit of the employees who are members of the Group savings plan 202,309,113 99.98% 49,625 0.02% 11,758 Agreed 27 amendment of Article 12 of the Articles of Association to conform with the new applicable legal provisions 202,346,226 99.99% 12,445 0.01% 11,825 Agreed 28 amendment of Article 23 of the Articles of Association 'Loss of half the share capital' to confirm with the new provisions of Article L. 225-248 of the French Commercial Code 202,335,661 99.99% 14,195 0.01% 20,640 Agreed Next on the agenda: Q2 2025 revenues, on July 23, 2025 (after market close) About Voltalia ( Voltalia is an international player in renewable energies. The Group produces and sells electricity from its wind, solar, hydro, biomass and storage facilities. It has 3.3 GW of capacity in operation and under construction, and a portfolio of projects under development with a total capacity of 17.4 GW. Voltalia is also a service provider, supporting its renewable energy customers at every stage of their projects, from design to operation and maintenance. A pioneer in the business market, Voltalia offers a comprehensive range of services to businesses, from the supply of green electricity to energy efficiency services and the local production of its own electricity. With more than 2,000 employees in 20 countries on 3 continents, Voltalia has the capacity to act globally on behalf of its customers. Voltalia is listed on the Euronext regulated market in Paris (FR0011995588 - VLTSA) and is included in the Enternext Tech 40 and CAC Mid&Small indices. The company is also included, amongst others, in the MSCI ESG ratings and the Sustainalytics ratings. VoltaliaEmail: invest@ +33 (0)1 81 70 37 00 Press Relations - Jennifer +33 (0)1 56 88 11 19 Attachment Information regarding the results of the vote on the resolutions presented (and all adopted) at the Annual General Meeting on May 15, 2025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Notice to attend the Extraordinary General Meeting of Sivers Semiconductors AB (publ)
NEW YORK, May 16, 2025 /PRNewswire/ -- The shareholders of Sivers Semiconductors AB (publ) (the "Company"), reg. no. 556383-9348, are hereby invited to attend the Extraordinary General Meeting to be held on Monday, 9 June 2025 at 3.00 pm at the Company's premises at Torshamnsgatan 48 in Kista, Sweden. The Board of Directors has decided that shareholders also have the opportunity to exercise their voting rights by postal voting prior to the Meeting. Right to participate and notice of participation at the Meeting Shareholders who wish to attend the Extraordinary General Meeting must: be recorded in the share register kept by Euroclear Sweden AB no later than on Wednesday 28 May 2025; and notify the Company their intention to participate no later than Monday 2 June 2025, via mail to the address Setterwalls Advokatbyrå AB, att: Niclas Töreki, Box 1050, 101 39 Stockholm or by email to The notification shall state name, personal identification number/ company registration number, daytime telephone number, number of shares held and proxies if applicable. Right to participate and notice by postal voting Shareholders who wish to participate in the Extraordinary General Meeting by postal voting must: be recorded in the share register kept by Euroclear Sweden AB no later than on Wednesday 28 May 2025; and give notice of participation no later than Monday 2 June 2025, by casting the postal vote in accordance with the instructions below so that the postal voting form is received by the Company no later than that day. A special form must be used for the postal vote. The form for postal voting is available on the Company's website, Completed and signed forms for postal voting can be sent via mail to the address Setterwalls Advokatbyrå AB, att: Niclas Töreki, Box 1050, 101 39 Stockholm or by email to Shareholders may not provide special instructions or conditions in the postal vote. If so, the entire postal vote is invalid. Further instructions and conditions may be found in the postal voting form. A shareholder who has voted by post may also attend the Meeting venue, provided that a notification has been made in accordance with the instructions under the heading "Right to participate and notice of participation at the Meeting" above. This means that postal voting does not constitute a notification also to attend the Meeting at the Meeting venue. Nominee registered shares To be entitled to participate in the Extraordinary General Meeting at the Meeting venue or by postal voting, shareholders whose shares are held in the name of a nominee must, in addition to providing notification of their participation in the Extraordinary General Meeting, re-register the shares in their own name so that the shareholders are registered in the share register on the record date on Wednesday 28 May 2025. This re-registration may be temporary (so-called "voting right registration") and is carried out through the nominee according to their procedures at a time predetermined by the nominee. Voting rights registration that has been completed by the nominee no later than 2 June 2025, are considered when preparing the share register. Voting rights registration can commence no earlier than Friday 23 May 2025. Proxies If shareholders wish to attend the Extraordinary General Meeting at the venue or by postal voting through a proxy, a written and dated power of attorney signed by the shareholder must be enclosed with the notification. The power of attorney form is available on the Company's website If the shareholder is a legal entity, a registration certification or an equivalent authorisation document must be enclosed along with the notification. Number of shares and votes As per 16 May 2025, there are a total of 285,657,897 shares corresponding to 272,338,958.1 votes in the Company, comprising 270,859,076 ordinary shares and 14,798,821 shares of series C. The Company owns 1,500,000 ordinary shares 14,798,821 shares of series C which may not be represented at the Meeting. Shareholders' right to request information The shareholders are reminded of their right, in accordance with Chapter 7 Section 32 of the Swedish Companies Act (2005:551), to request information from the Board and the CEO at the Meeting. For information on how personal data is processed, see: Proposal for agenda Election of Chairman of the Meeting Election of one or two persons to verify the minutes Preparation and approval of the voting list Approval of the agenda Determination as to whether the Meeting has been duly convened Approval of the Board of Directors' resolution on a directed new issue of warrants Election of Chairman of the Meeting (item 1) The Board of Directors proposes that Attorney at law Jörgen S. Axelsson is elected as Chairman of the Meeting. Approval of the Board of Directors' resolution on a directed new issue of warrants (item 6) The Board of Directors proposes that the Extraordinary General Meeting resolves to approve the Board of Directors' resolution from 15 May 2025, on a directed new issue of warrants on the following terms: A maximum of 3,318,029 warrants shall be issued. By way of deviation from the shareholders' preferential rights, the warrants shall be subscribed for solely by Century Bank. The rationale for deviating from the shareholders' preferential rights is to issue warrants within the scope of the Company's debt financing. Subscription shall take place no later than 9 June 2025. The warrants are issued free of charge. No oversubscription shall be permitted. The warrants shall be subject to the terms and conditions set out in the attached warrant terms for 2025/2030 as Appendix 1 (the "Warrant Terms"). Each warrant entitles its holder to subscribe for one (1) new ordinary share in the Company, with a quota value of SEK 0.50 per share, at a subscription price per share of SEK 4.53. Any portion of the subscription price exceeding the quota value of the Company's shares shall be allocated to the unrestricted share premium reserve. The subscription price and the number of shares that each warrant entitles the holder to subscribe for may be subject to adjustment in accordance with Section 8 of the Warrant Terms. The warrants may be exercised for subscription of shares from and including the date on which the warrants are registered with the Swedish Companies Registration Office until 9 May 2030. The date for exercising the warrants may be brought forward or postponed in accordance with Section 7 of the Warrant Terms. Shares issued upon exercise of the warrants shall qualify for dividends from the first record date for dividend that occurs immediately after the shares have been subscribed. Upon full exercise of the warrants for subscription of new shares, the share capital shall increase by SEK 1,659,014.50. The reasons for initiating the warrant program and deviating from the shareholders' preferential rights are that the Company has taken out new debt financing, under which the lender is to receive warrants. It was noted that the documents required under Chapter 14, Section 8 of the Swedish Companies Act had been duly presented. For a resolution pursuant to this item 6 to be valid, it must be supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting. The Board shall be authorized to make any minor formal adjustments to the resolution that may prove necessary in connection with its registration with the Swedish Companies Registration Office. A resolution pursuant to this item 6 is only valid if approved by shareholders representing at least two thirds of the votes cast as well as the shares represented at the General Meeting. Documents Documents to be handled at the Meeting are available to shareholders at the Company's head office at the address Torshamnsgatan 48 in Kista, Sweden and on the Company's website Copies of the documents will be sent free of charge to shareholders who so request and who provide their mailing address. Kista in May 2025Sivers Semiconductors AB (publ)The Board of Directors For more information please contact:Vickram Vathulya CEO, Sivers SemiconductorsTel: +46 (0)8 703 68 00Email: ir@ About Sivers Semiconductors We are Critical Enablers of a Greener Data Economy with Energy Efficient Photonics & Wireless Solutions. Our differentiated high precision laser and RF beamformer technologies help our customers in key markets such as AI Data Centers, SATCOM, Defense and Telecom solve essential performance challenges while enabling a much greener footprint. Visit us at: ( This information was brought to you by Cision The following files are available for download: Notice to EGM_PR_EN_ 2025-05-16 View original content: SOURCE Sivers Semiconductors Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission
MALMÖ, SE / / May 16, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker: ACE) today published its Interim Report Q1 for 2025 (January - March), which is now available on the company's website: Financial Reports - ASCELIA KEY EVENTS IN Q1 2025 Three scientific abstracts with Orviglance® SPARKLE Phase 3 data accepted for presentation at the ESGAR congress 2025 Extraordinary General Meeting on 25 February 2025 to adopt an employee stock option proposal Nomination Committee appointed for AGM 2025 in Ascelia Pharma AB Announcement of positive outcome of FDA Meeting and confirmed plan to submit the NDA for Orviglance mid-2025 Subscription price for warrants series TO 1 determined to SEK 2.15 and exercise period initiated on 1 April 2025 KEY EVENTS AFTER THE PERIOD Study on Orviglance target patients accepted for presentation at the ISPOR 2025 conference Publication of scientific article on Orviglance in Investigative Radiology Ascelia Pharma receives gross proceeds of SEK 43 million from exercise of warrants series TO 1 Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025 FINANCIAL SUMMARY Q1 (Jan-Mar) 2025 Operating result of SEK -20.3M (SEK -16.7M) Earnings per share of SEK -0.23 (SEK -0.49) Cash flow from operations of SEK -16.9M (SEK -15.0M) Liquid assets and marketable securities of SEK 57.3M (SEK 26.5M) "Clinical development for our lead asset, Orviglance, is successfully completed with consistent positive efficacy and safety results from nine clinical studies with a total of 286 patients and healthy volunteers. In our Phase 3 study, SPARKLE, Orviglance significantly improved visualization of focal liver lesions in patients with impaired kidney function, meeting the primary endpoint with statistical significance for all three readers (<0.001). We are now focusing on bringing Orviglance through the regulatory approval process. In March 2025, we announced the outcomes from our planned meeting with the US Food and Drug Administration (FDA). The meeting provided clear and concrete guidance for the Orviglance NDA. Incorporating the detailed FDA feedback from this meeting into the NDA is progressing well and we continue to expect submission by mid-year 2025, most likely during the first half of August. It's encouraging to see the medical community welcoming Orviglance data for presentation in four oral presentations and four abstracts at key scientific conferences thus far. In April 2025, a new scientific publication in Investigative Radiology was published featuring Orviglance in a comparison study to unenhanced MRI and to gadolinium. We were pleased to see the successful outcome of the TO 1 warrants exercise, which provided SEK 43 million additional financing before costs with a subscription rate of 96 percent in April 2025. This strengthens our financial flexibility. We now have a cash runway to at least end 2025, well beyond the NDA submission and repayment of the SEK 20 million loan to Fenja with reserved cash for a potential repayment of the SEK 7.5 million convertibles end of 2025. This runway excludes financing from partnering. We are excited about our continued progress with Orviglance and are in a strong position to submit the NDA according to plan. We are also progressing our partnership discussions for the commercialization of Orviglance and look forward realizing the potential of Orviglance and provide better access to diagnosis and care for cancer patients with impaired kidney function." , said Magnus Corfitzen, CEO at Ascelia Pharma.A presentation for analysts, investors and media will be held today 16 May at 10:00am CET. The event will be hosted by the company's CEO Magnus Corfitzen, Deputy CEO Julie Waras Brogren, and CSO Andreas Norlin. The presentation will be held in English. The presentation can be followed live via the link: Q1 Report 2025 To participate via teleconference, please register through the link below. After registration, you will be provided with phone numbers and a conference ID to access the conference: Call AccessIt will also be possible to access the audiocast afterwards at the same address or on the website of Ascelia Pharma: IR & Media - ASCELIA About us Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates - Orviglance and Oncoral - in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit About us About Ascelia PharmaAscelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates - Orviglance® (Mangoral) and Oncoral - in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit . About OncoralOncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is now prepared for Phase 2 clinical development. Attachments Ascelia Pharma Q1 2025 EN 250515 SOURCE: Ascelia Pharma View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
